To assess the safety of lornoxicam with particular focus on gastrointestinal (GI) events.
Data on adverse drug reactions (ADRs) were pooled from 60 comparative studies of lornoxicam.
A total of 6420 patients received lornoxicam, 1192 received placebo and 3770 received a comparator analgesic. ADRs were reported by 21% of lornoxicam-treated patients, with GI events the most frequent (14 vs 8% with placebo). Across 15 studies that compared lornoxicam (n = 1287) with another NSAID (n = 1010), there was a reduced risk of a GI ADR with lornoxicam (0.78 [95% CI: 0.64-0.96]; p = 0.017).
Lornoxicam was well tolerated with the type of GI events observed consistent with the known safety profile of NSAIDs.